<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5197-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IMTUS 20MG/ML SOL. FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRINOTECAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        179.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Emcure Pharmaceuticals Ltd. " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Emcure Pharmaceuticals Ltd. 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 416]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Arabian Health Care Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Emcure Pharmaceuticals Ltd. 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XX19 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>WHAT IMTUS IS AND WHAT IT IS USED FOR<br />Your medicine is called Imtus. Imtus belongs to a group of medicines called cytostatics<br />(anti- cancer medicines).<br />Imtus may be used alone or in combination with a number of other medicines<br />used to treat cancer. These combinations may be used to treat cancers of the<br />large intestine (colon or rectum) where the disease is at an advanced stage.<br />Your doctor may use a combination of Imtus with 5-fluorouracil/folinic acid (5FU/FA) and<br />bevacizumab to treat your cancer of the large intestine (colon or rectum).<br />Your doctor may use a combination of Imtus with capecitabine with or without<br />bevacizumab<br />to treat your cancer of the colon and rectum.<br />Your doctor may use a combination of Imtus with cetuximab to treat a particular type<br />of cancer of the large intestine (KRAS wild-type) which expresses a protein called EGFR.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You should not be given Imtus if any of the following apply to you:<br />- If you are allergic to irinotecan hydrochloride or any of the other ingredients of<br />Imtus<br />- If you have or have had chronic inflammatory bowel disease or bowel obstruction<br />- If you are pregnant or breast feeding or if you think you might be pregnant<br />- If you have severe liver disease<br />- If you have severe bone marrow failure<br />- If your general health status does not allow you to carry out general activities of<br />daily living<br />- If you are taking St Johns&rsquo; Wort (a herbal supplement)<br />Take special care with Imtus<br />Before treatment with Imtus tell your doctor if any of the following apply to you:<br />- You have liver problems or jaundice<br />- You have kidney problems<br />- You have asthma<br />- You have ever received radiation therapy<br />- You experienced severe diarrhoea or fever after being treated with Imtus before.<br />- You have heart problems<br />- You smoke, have high blood pressure or high cholesterol as these can increase<br />the risk of heart problems during treatment with Imtus<br />- You have had or are due to have any vaccinations<br />You are taking any other medicines. Please see the section below &ldquo;Taking other<br />medicines&rdquo;.<br />As with all anti-cancer medicines the use of Imtus is associated with a number of sideeffects<br />which may be serious. These side-effects require special management to minimise the risk of complications.<br />You will be treated by a specialist team experienced in using these kinds of treatments and<br />managing their side effects, which are usually temporary. However, it is essential that you<br />read<br />the section &ldquo;POSSIBLE SIDE EFFECTS&rdquo; and follow the instructions carefully if you<br />get any of the symptoms described.<br />Taking other medicines:<br />Please tell your doctor if you are taking or have recently taken any other medicines,<br />including medicines obtained without a prescription.<br />If you receive Imtus in combination with either capecitabine, cetuximab or<br />bevacizumab, please make sure that you also read the patient information leaflet for<br />each medicine.<br />Some medicines, when taken at the same time as Imtus, may affect the way Imtus works or<br />Imtus may affect the way they work. Tell your doctor if you are taking any of the following<br />medicines:<br />- St John&rsquo;s Wort (a herbal supplement)<br />- Ketoconazole (an antiobiotic)<br />- Rifampicin (an antiobiotic)<br />- Carbamazepine (used to treat seizures)<br />- Phenobarbital (used to treat seizures)<br />- Phenytoin (used to treat epilepsy)<br />- Warfarin (an anticoagulant used to thin the blood)<br />- Atazanavir (used to treat HIV)<br />- Ciclosporin or Tacromilus (used to dampen down your body&rsquo;s immune system)<br />If you go into hospital to have an operation, tell the anaesthetist and the medical staff<br />that you are being treated with Imtus and any other medicines you are taking<br />Pregnancy and breast-feeding.<br />You must not use Imtus if you are pregnant as it may harm your unborn baby.<br />You should also avoid becoming pregnant while you are being treated with Imtus.<br />Men and Women should use adequate contraception while being treated with Imtus<br />and for:<br />&bull; Up to 1 month after you receive your last dose of Imtus if you are female<br />&bull; Up to 3 months after your last dose of Imtus if you are male.<br />If you do become pregnant while being treated with Imtus you must inform your doctor<br />IMMEDIATELY.<br />Because Imtus may be harmful to nursing infants, women must not breast-feed while being<br />treated with Imtus.<br />Driving and Using Machines<br />Imtus may make you feel dizzy or cause visual disturbances. If this happens to you do not<br />drive or operate machinery until this resolves.<br />Important Information about some of the ingredients of<br />Imtus Warning:<br />This medicine contains sorbitol, a type of sugar. If you have been told by your doctor that<br />you have an intolerance to some sugars tell your doctor or nurse before you are given<br />Imtus.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>If you are prescribed Imtus it will only be given to you by doctors or nurses experienced in<br />giving chemotherapy.<br />Method of administration: Imtus will be given as an infusion into your veins over a<br />period of 30 to 90 minutes.<br />If you receive Imtus in combination with cetuximab, Imtus must not be administered earlier<br />than 1 hour after the end of the cetuximab infusion.<br />Dosage and frequency of administration:<br />The amount of Imtus you are given will depend on your age, size and general medical<br />condition. It will also depend on any other treatment you may have received for your<br />cancer.<br />Your doctor will calculate your body surface area in square metres (m2).<br />&bull; If you have previously been treated with 5-fluorouracil you will normally be treated<br />with Imtus alone starting with a dose of 350 mg/m2 every three weeks.<br />&bull; If you have not had previous chemotherapy you will normally receive 180 mg/m2<br />Imtus every two weeks. This will be followed by folinic acid and 5-fluorouracil.<br />These dosages may be adjusted by your doctor depending on your condition and any side effects you may have.<br />Duration of treatment:<br />The number of infusions that you receive will depend on how you are responding to<br />treatment. Your doctor will discuss this with you.<br />Blood Monitoring<br />Whilst you are taking Imtus and/or other similar medicines you will have regular blood<br />tests to monitor your treatment and to ensure that there are no untoward adverse effects.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>4. POSSIBLE SIDE EFFECTS<br />Medicines like Imtus will cause unwanted side-effects.<br />Your doctor will discuss these side-effects with you and explain the risks and benefits of<br />your treatment.<br />Some of these side-effects must be treated IMMEDIATELY.<br />Please read the following instructions carefully and follow them if you have any of the<br />side-effects listed.<br />Diarrhoea<br />Imtus may cause you to have diarrhoea. There are two types of diarrhoea, which can be<br />distinguished by when they start. &ldquo;Early&rdquo; diarrhoea starts less than 24 hours after the<br />infusion and &ldquo;delayed&rdquo; diarrhoea starts more than 24 hours after the infusion. If you have<br />ANY DIARRHOEA it is IMPORTANT that you follow these instructions carefully.<br />Early diarrhoea<br />If your diarrhoea starts less than 24 hours after the infusion (&ldquo;early diarrhoea&rdquo;) you<br />should contact your doctor or nurse IMMEDIATELY and they will give you a suitable<br />treatment.<br />This &ldquo;early diarrhoea&rdquo; may be accompanied by other symptoms such as:<br />&bull; Sweating<br />&bull; Chills<br />&bull; Abdominal cramps<br />&bull; Watering eyes<br />&bull; Stuffy nose<br />&bull; Visual disturbance<br />&bull; Dizziness<br />&bull; Low blood pressure<br />&bull; Feeling unwell<br />&bull; Feeling weak<br />&bull; Excessive mouth watering<br />&bull; Pupils of the eye get smaller<br />Tell your doctor or nurse about all your symptoms.<br />Do not use any anti-diarrhoeal treatment that your doctor has given you for &ldquo;delayed<br />diarrhoea&rdquo;.<br />Delayed Diarrhoea<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;If &nbsp; your &nbsp; diarrhoea &nbsp; starts &nbsp; more &nbsp; than &nbsp; 24 &nbsp; hours &nbsp; after &nbsp; the &nbsp; infusion &nbsp;&nbsp;<br />(&ldquo;delayed diarrhoea&rdquo;) you should IMMEDIATELY take any anti-diarrhoeal treatment that the doctor has&nbsp;<br />given you EXACTLY as he has told you. If you are unsure of what this is, ask your doctor or nurse.</p><p>Drink large amounts of rehydration fluids, IMMEDIATELY (i.e. water, soda water, fizzy drinks, soup&nbsp;<br />or oral rehydration therapy).<br />You must tell your doctor if:<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;You have nausea and vomiting as well as diarrhoea<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;You have any fever as well as the diarrhoea<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;You still have diarrhoea 48 hours after starting the diarrhoea treatment</p><p><br />Do not take any treatment for diarrhoea other than that given to you by your doctor or nurse and&nbsp;<br />only drink the fluids described above.</p><p>Decrease in white blood cells</p><p>Imtus may cause a decrease in the number of some of your white blood cells, which play an important&nbsp;<br />role in fighting infections. This is called neutropenia.<br />Your doctor will probably arrange for you to have regular blood tests to monitor these<br />white blood cells.</p><p>If you have any fever this may be an indication of infection associated with this<br />neutropenia<br />and requires immediate treatment.</p><p><br />If you have any fever, and particularly if you also have diarrhoea, contact your doctor or nurse&nbsp;<br />IMMEDIATELY so that they can give you necessary treatment.<br />Nausea and vomiting<br />If you have nausea and/or vomiting contact your doctor or nurse IMMEDIATELY.</p><p>Breathing difficulties</p><p>If you have breathing difficulties contact your doctor or nurse<br />IMMEDIATELY. Other side effects<br />All medicines can cause allergic reactions. If you experience any of the following conditions&nbsp;<br />please report it to a doctor or nurse IMMEDIATELY:<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Wheeziness<br />Difficulty in breathing<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Swelling<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Rash or itching (especially affecting the whole body)<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Dehydration<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Kidney problems<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Low blood pressure<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Heart problems<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Blockage or perforation (a &lsquo;hole&rsquo;) in the bowel<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Bleeding from the bowel<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Inflammation in the bowel<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Inflammation of the pancreas<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Severe stomach pain<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Passing black or blood stained stools<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Vomiting blood<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Changes in laboratory tests<br />If &nbsp;you &nbsp;receive &nbsp;Imtus &nbsp;in &nbsp;combination &nbsp;with &nbsp;cetuximab, &nbsp;some &nbsp;of &nbsp;the &nbsp;side &nbsp;effects &nbsp;you &nbsp;may&nbsp;<br />experience can also be related to this combination. Such side effects may include a acne- like &nbsp;<br />rash. &nbsp;Therefore, &nbsp;please &nbsp;make &nbsp;sure &nbsp;that &nbsp;you &nbsp;also &nbsp;read &nbsp;the &nbsp;package &nbsp;leaflet &nbsp;for<br />cetuximab.<br />If you receive Imtus in combination with capecitabine, some of the side effects you may experience &nbsp;<br />can &nbsp;also &nbsp;be &nbsp;related &nbsp;to &nbsp;this &nbsp;combination. &nbsp;Such &nbsp;side &nbsp;effects &nbsp;may &nbsp;include: &nbsp;very common&nbsp;<br />blood clots, common allergic reactions, heart attack and fever in patients with a low &nbsp;white &nbsp;blood&nbsp;<br />&nbsp;cell &nbsp;count. Therefore, &nbsp;please &nbsp;make &nbsp;sure &nbsp;that &nbsp;you &nbsp;also &nbsp;read &nbsp;the &nbsp;package leaflet for&nbsp;<br />capecitabine.</p><p>If you receive Imtus in combination with capecitabine and bevacizumab, some of the side effects &nbsp;<br />you &nbsp;may &nbsp;experience &nbsp;can &nbsp;also &nbsp;be &nbsp;related &nbsp;to &nbsp;this &nbsp;combination. &nbsp;Such &nbsp;side &nbsp;effects include: &nbsp;<br />low &nbsp;white &nbsp;blood &nbsp;cell &nbsp;count, &nbsp;blood &nbsp;clots, &nbsp;high &nbsp;blood &nbsp;pressure &nbsp;and &nbsp;heart &nbsp;attack.&nbsp;<br />Therefore, please make sure that you also read the package leaflet for capecitabine and<br />bevacizumab.<br />Other side effects which may occur when you are treated with Imtus are:<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Hair loss<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Fatigue<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Loss of appetite<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&bull; &nbsp; &nbsp; &nbsp; &nbsp;Mild allergic skin reactions<br />&bull; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Mild stomach pains<br />&bull; Muscular cramps and twitches<br />&bull; Pins and needles<br />&bull; Constipation<br />&bull; Inflammation at the injection site<br />&bull; Mouth ulcers<br />&bull; Temporary speech disorders<br />&bull; High blood pressure<br />If any of the side effects get serious, or if you notice any side effects not listed in this<br />leaflet, please tell your doctor or nurse immediately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 30&deg;C.<br />Protect from light. Store in carton. Protect from freezing.<br />Once the concentrate has been diluted for infusion the solution can be kept for 24 hours in<br />a refrigerator (at 2 to 8&deg;C).<br />Do not use Imtus after the expiry date which is stated on the vial and on the box after<br />&ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Imtus contains<br />The active substance is irinotecan hydrochloride.<br />The other ingredients are sorbitol, lactic acid, sodium hydroxide, hydrochloric acid, &amp;<br />water for injection.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Imtus looks like and contents of the pack
Imtus is a liquid in a vial with rubber stopper. Each 2ml vial contains 40mg of Irinotecan or
5 ml vial contains 100mg of Irinotecan.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Emcure Pharmaceuticals LTD., Hinjwadi, Pune 411 057, India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised on December, 2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو إمتس وماهي استخداماته:<br />دواء إمتس ينتمي الي مجموعة من الادوية تسمي مثبطات الخلايا (الادوية المضادة للسرطان) &nbsp;<br />من الممكن استخدام إمتس منفردًا أو بإضافته لعدد اخر من الادوية التي تستخدم لعلاج السرطان. هذا الدمج بالأدوية يستخدم في علاج سرطان الأمعاء الغليظة (القولون والمستقيم) حينما يكون المريض في مراحله المتقدمة.<br />يمكن للطبيب استخدام إمتس بدمجة مع دواء خماسي الفلوروسيل مع حمض الفولينيك وبيفاسيزيوماب لعلاج سرطان القولون والمستقيم&nbsp;<br />يمكن للطبيب استخدام إمتس بدمجة مع دواء كابسيتابين مع أو بدون بيفاسيز لعلاج سرطان الأمعاء الغليظة (والقولون والمستقيم<br />يمكن للطبيب استخدام إمتس بدمجة مع دواء سيتيوكسيماب لعلاج نوع معين من سرطان الأمعاء الغليظة (النوع الجامح من سرطان الجين كراس &ndash; KRAS Wild type) والذي يظهر من خلال استخلاص بروتين يسمي &ndash; مستقبل عوامل نمو البشرة ((EDFR</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا يجب استخدام إمتس في أي من الحالات التالية:<br />- إذا كنت تعاني من حساسية ضد ارينوتيكان هيدرو كلوريد أو أي من مكوناته.<br />- إذا كنت تعاني أو عانيت مسبقا من التهاب الأمعاء المزمن أو انسداد الأمعاء.<br />- إذا كنتي حامل أو تقومين بالرضاعة أو تعتقدين أنك قد تكونين حامل.<br />- إذا كنت تعاني من أمراض الكبد الشديدة.<br />- إذا كنت تعاني من فشل في نخاع العظام.<br />- إذا كانت الحالة العامة لصحتك لا يسمح بتنفيذ الأنشطة العامة واليومية.<br />- إذا كنت تتناول نبتة سانت جورج (مكمل عشبي)<br />خذ بالاعتبار عناية خاصة مع استخدام إمتس&nbsp;<br />أخبر طبيبك قبل تناول دواء إمتس إذا كان أي مما يلي ينطبق على حالتك&nbsp;<br />- إذا كنت تعاني من مشكلات بالكبد أو من اليرقان (الصفراء)<br />- إذا كنت تعاني من مشكلات بالكلي.<br />- إذا كنت تعاني من الربو.<br />- إذا كنت تعالج بالعلاج الإشعاعي.<br />- إذا كنت قد عانيت من الإسهال والحمى بعد العلاج مسبقا باستخدام إمتس&nbsp;<br />- إذا كنت تعاني من مشكلات بالقلب.<br />- إذا كنت تدخن أو تعاني من ضغط الدم المرتفع أو ارتفاع نسبة الكوليسترول لان هذا يزيد من مخاطر حدوث مشكلات القلب أثناء العلاج باستخدام إمتس.<br />- إذا كنت تتعاطي التحصينات.<br />- إذا كنت تتناول أدوية اخرى. رجاء النظر بفقرة (تناول الادوية الأخرى)&nbsp;<br />مثل كافة الادوية المستخدمة لعلاج السرطان استخدام إمتس يرتبط بحدوث عدد من الاثار الجانبية والتي من الممكن ان تكون خطيرة. هذه الاثار الجانبية تتطلب رعاية خاصة من اجل التقليل من مخاطر المضاعفات.<br />سوف يتم علاجك تحت اشراف فريق من المتخصصين ذوي الخبرة في التعامل مع هذا الادوية والتعامل مع اثارها الجانبية والتي عادة تكون مؤقتة. وبالرغم من ذلك من الضروري قراءة فقرة (الاثار الجانبية المحتملة) واتباع التعليمات بحرص إذا عانيت من أحد الأعراض المذكورة.<br />تناول الادوية الأخرى&nbsp;<br />برجاء اخبار طبيبك إذا كنت تناولت مؤخرا أدوية اخرى بما في ذلك الادوية التي تؤخذ دون وصفة طبية&nbsp;<br />. إذا كنت تتناول دواء إمتس مع أحد الادوية كابسيتابين أو سيتيوكسيماب أو بيفاسيزيوماب برجاء التأكد من أنك قد قرأت &nbsp;<br />النشرات الداخلية لكل دواء<br />بعض الادوية التي تؤخذ في نفس الوقت مع إمتس من الممكن ان تؤثر على عمل دواء إمتس أو ان دواء إمتس من الممكن ان يؤثر على عمل هذا الادوية. رجاء اخبار طبيبك إذا كنت تتناول أي من الادوية التالية:<br />- نبتة سانت جورج (مكمل غذائي)<br />- كيتوكونازول (مضاد حيوي)&nbsp;<br />- ريفامبيسين (مضاد حيوي)&nbsp;<br />- كاربامازيبين (يستخدم لعلاج التشنجات)<br />- فينو باربيتال (يستخدم لعلاج التشنجات)&nbsp;<br />- فينيتوين (يستخدم لعلاج حالات الصرع)<br />- وارفارين (مضاد للتجلط يستخدم تخفيف الدم)&nbsp;<br />- اتازانافير (يستخدم لعلاج فيروس نقص المناعة البشرية)<br />- سيكلوسبورين أو تاروليماس (يستخدم لتهدئة جهاز المناعة بالجسم)<br />إذا تم ايداعك في المستشفى لأجراء عملية جراحية برجاء اخبار متخصص التخدير والفريق الطبي أنك تعالج بإمتس وأيضا الادوية الأخرى التي تتناولها.<br />الحمل والرضاعة&nbsp;<br />لا يجب استخدام دواء إمتس اذا كنتي حاملا لان هذا ربما يضر بالجنين.<br />لابد من تجنب حدوث الحمل إذا كنتي تعالجين باستخدام إمتس&nbsp;<br />لابد للرجال والنساء استخدام موانع الحمل طالماً يعالجون باستخدام إمتس وذلك لمدة:<br />-حتى شهر واحد بعد تناول أخرب جرعة من دواء إمتس إذا كنتي أنثي&nbsp;<br />-حتى ثلاثة شهور بعد تناول اخر جرعة من دواء إمتس إذا كنت ذكر.<br />إذا أصبحتِ حامل وأنتي تعالجين باستخدام دواء إمتس يجب عليك إخبار طبيبك في الحال&nbsp;<br />على الأم ألا تقوم بإرضاع الأطفال أثناء العلاج باستخدام دواء إمتس حيث أنه ربما يكون ضارا بالنسبة لهم.<br />القيادة واستخدام الاّلات&nbsp;<br />من الممكن ان يتسبب إمتس في الإصابة بالدوار أو إختلال الرؤية ولذلك إذا حدث هذا لا بد أن تتوقف عن القيادة واستخدام الآلات لحين حل ما حدث.<br />معلومات هامة عن بعض من مكونات إمتس&nbsp;<br />تحذير:<br />هذا الدواء يحتوي على مادة سوربيتول وهي نوع من السكر إذا اخبرك طبيبك بانك تعاني من حساسية مفرطة لبعض أنواع السكر برجاء اخبار طبيبك أو الممرضة قبل إعطائك إمتس<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كيفية استخدام إمتس.<br />إذا تم وصف إمتس لك فسيتم إعطاؤه لك من قبل أطباء أو ممرضات من ذوي الخبرة في إعطاء العلاج الكيميائي&nbsp;<br />طريقة الاستخدام: سيتم إعطاء إمتس بمثابة تنقيط عبر الأوردة خلال فترة من 33 الي 30 دقيقة.<br />إذا تم إعطاؤك إمتس مع سيتي كسيماب. يجب عدم إعطاء إمتس قبل ساعة واحدة بعد نهاية حقن سيتيوكسيماب.<br />الجرعة وتكرار الاستخدام&nbsp;<br />تعتمد كمية إمتس التي تحصل عليها على عمرك وحجمك وحالتك الطبية العامة وسوف يعتمد أيضا على أي علاج اخر ربما تكون قد تلقيته لعلاج السرطان&nbsp;<br />سيقوم الطبيب بحساب مساحة سطح الجسم في متر مربع (م 2)&nbsp;<br />إذا كنت قد تم علاجك سابقا بخماسي الفلورورسيل فعادة ما يتم علاجك باستخدام إمتس منفردا بجرعة تبدأ من 353 مجم /م2 كل ثلاثة أسابيع.<br />إذا لم تكن قد تلقيت علاجا كيميائيا مسبقا فستحصل عادة على 183مجم / م2 من إمتس كل أسبوعين سيتبع ذلك حمض الفولينيك وخماسي فلورويوراسيل.<br />ويمكن للطبيب تعديل هذه الجرعات من قبل الطبيب المتابع لحالتك واي اثار جانبية تحدث لك.<br />مدة العلاج&nbsp;<br />يعتمد عدد جرعات التنقيط الوريدي التي تتلقاها على كيفية استجابتك للعلاج وسوف يقوم طبيبك بمناقشة هذا معك<br />مراقبة الدم:<br />بينما تتناول دواء إمتس أو أدوية اخرى مماثلة سوف يكون هناك اختبارات منتظمة للدم لمراقبة علاجك وللتأكد من انه لا يوجد اثار جانبية غير مرغوب فيها&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>الاثار الجانبية المحتملة:<br />إمتس من الادوية التي سوف تسبب اعراض جانبية غير مرغوبة سوف يناقش طبيبك هذه الاثار الجانبية معك وسوف يشرح لك مخاطر وفوائد علاجك. وبعض من الاثار الجانبية يجل معالجتها في الحال.<br />يرجي قراءة التعليمات التالية بعناية ومتابعتها إذا كان لديك أي من الاثار الجانبية المذكورة&nbsp;<br />الإسهال<br />قد يسبب لك إمتس الإصابة بالإسهال هناك نوعان من الإسهال والتي يمكن تمييزها حين تبدأ الإسهال المبكر بعد 24 ساعة من التنقيط الوريدي ويبدأ الإسهال المتأخر بعد 24 ساعة من التنقيط الوريدي إذا كنت تعاني من أي حالة إسهال فمن المهم ان تتبع التعليمات بعناية.<br />الإسهال المبكر:<br />إذا بداء الإسهال بعد اقل من 24 ساعة من التنقيط الوريدي) الإسهال المبكر يجب عليك الاتصال بالطبيب أو الممرضة على الفور وسيعطيك العلاج المناسب&nbsp;<br />قد يصاحب هذا الإسهال المبكر أعراضا اخرى مثل:<br />- التعرق &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- قشعريرة &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - المغص&nbsp;<br />- عيون دامعة &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - انسداد الأنف &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - اختلال في الرؤية&nbsp;<br />- الدوار &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - انخفاض ضغط الدم &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - الشعور بعدم الراحة&nbsp;<br />- الشعور بالضعف &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - سيلان اللعاب &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - &nbsp;صغر حدقة العين&nbsp;<br />أخبر طبيبك أو الممرض عن جميع الأعراض.<br />لا تستخدم أي علاج مضاد للإسهال قدمه لك طبيبك للإسهال المتأخر&nbsp;<br />الإسهال المتأخر:<br />إذا كان الإسهال يبدا بعد أكثر من 24 ساعة من التنقيط الوريدي (الإسهال المتأخر) يجب عليك فورا تناول أي علاج مضاد للإسهال وصفة لك الطبيب كما اخبرك. إذا كنت غير متأكد من ماهيته فأسأل الطبيب أو الممرضة.<br />قم بشرب كميات كبيرة من سوائل الاماهة على الفور (المياه، المياه الغازية، المشروبات الغازية، حساء أو علاج الجفاف عن طريق الفم).<br />يجب عليك اخبار طبيبك إذا:<br />- كنت تعاني من الغثيان والقيء وكذلك الإسهال&nbsp;<br />- كنت تعاني من أي حمي وكذلك الإسهال&nbsp;<br />- كنت لازلت تعاني من الإسهال بعد 48 ساعة من بدء علاج الإسهال&nbsp;<br />لا تأخذ أي علاج للإسهال غير الذي يعطيه لك الطبيب أو الممرضة ولا تشرب ألا السوائل الموصوفة أعلاه&nbsp;<br />انخفاض في خلايا الدم البيضاء:<br />قد يتسبب إمتس في انخفاض عدد خلايا الدم البيضاء التي تلعب دورا مهما في مكافحة العدوي وهذا يسمي بنقص الكريات البيضاء&nbsp;<br />من المحتمل ان يقوم طبيبك بترتيب فحوصات دم منتظمة لمراقبة خلايا الدم البيضاء&nbsp;<br />إذا كان لديك أي حمي قد يكون هذا مؤشرا للعدوي المرتبطة بهذا النقص في الكريات البيضاء ويتطلب العلاج الفوري&nbsp;<br />إذا كانت لديك أي حمي وخاصة إذا كنت تعاني من الإسهال فاتصل بطبيبك أو ممرضك على الفور حتى يتمكن من إعطائك العلاج الازم.<br />القيء والغثيان&nbsp;<br />إذا كنت تعاني من الغثيان أو التقيؤ فاتصل بطبيبك أو ممرضك على الفور&nbsp;<br />صعوبة في التنفس&nbsp;<br />إذا كنت تعاني من مشكلات في التنفس فاتصل بطبيبك أو ممرضك على الفور<br />اثار جانبية اخرى<br />يمكن لجميع الادوية ان تسبب الحساسية إذا كنت تعاني من أي من حالات التالية يرجي إبلاغ طبيبك أو ممرضك على الفور<br />- الأزيز &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - صعوبة في التنفس &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - التورم&nbsp;<br />- طفح أو حكة (تؤثر على الجسم بالكامل) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - الجفاف&nbsp;<br />- انخفاض ضغط الدم &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - مشكلات في القلب &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- مشكلات في الكلي&nbsp;<br />- النزيف بالأمعاء &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - انسداد بالأمعاء &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - التهاب الأمعاء&nbsp;<br />- التهاب البنكرياس &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - الم شديد بالمعدة &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; براز اسود أو براز ملطخ بالدم&nbsp;<br />- قيء دموي &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- تغيرات بالاختبارات المعملية&nbsp;<br />إذا كنت تتلقي دواء إمتس بدمجة بدواء سيتيوكسيماب بعض من الاثار الجانبية التي يمكن ان تحدث لك من الممكن ان تكون لها علاقة بهذا العلاج هذه الاثار الجانبية من الممكن ان تشمل الطفح الجلدي نتيجة بثور حب الشباب وبالتالي تأكد من قراءة النشرة الداخلية لدواء سيتيوكسيماب.<br />إذا كنت تتلقي دواء إمتس بدمجة مع دواء كابسيتابين بعض من الاثار الجانبية التي يمكن ان تحدث لك من الممكن تكون لها علاقة بهذا العلاج هذه الاثار الجانبية من الممكن ان تشمل تجلطات دموية، تفاعلات حساسية، نوبات قلبية وحمي في مرضي انخفاض نسبة كرات الدم البيضاء. وبالتالي تأكد من قراءة النشرة الداخلية لدواء كابسيتابين.<br />إذا كنت تتلقي دواء إمتس بدمجة مع دواء كابسيتابين وبيفاسيزوماب بعض من الاثار الجانبية التي يمكن ان تحدث لك من الممكن أن تكون لها علاقة بهذا العلاج هذه الاثار الجانبية من الممكن ان تشمل تجلطات دموية، تفاعلات حساسية، نوبات قلبية وحمي وفي بعض المرضي انخفاض نسبة كرات الدم البيضاء. وبالتالي تأكد من قراءة النشرة الداخلية لدواء كابسيتابين وبيفاسيزيوماب<br />اثار جانبية اخرى من الممكن ان تحدث عند العلاج باستخدام إمتس:<br />- تساقط الشعر &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - الإرهاق &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- فقدان الشهية&nbsp;<br />- تفاعلات حساسية متوسطة الشدة &nbsp; &nbsp; - اللام في المعدة متوسطة الشدة &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- تشنجات عضلية&nbsp;<br />- إحساس بالوخز &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- الإمساك &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;- التهاب في موضع الحقن&nbsp;<br />- قرح الفم &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - اضطربات مؤقتة في الكلام &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; - ارتفاع ضغط الدم&nbsp;<br />إذا كنت أي من الاثار الجانبية الخطيرة، أو إذا لاحظت أي اثار غير مدرجة في هذه النشرة يرجي اخبار الطبيب أو الممرضة على الفور:<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كيفية تخزين إمتس&nbsp;<br />يحفظ بعيدا عن رؤية ومتناول الأطفال&nbsp;<br />يحفظ في درجة حرارة اقل من 33 درجة مئوية&nbsp;<br />يجب حمايته من الضوء، وتخزينه داخل كرتون وحمايته من التجمد&nbsp;<br />بمجرد تخفيف السائل المركز للتنقيط الوريدي فيمكن حفظ السائل لمدة 24 ساعة في الثلاجة عند درجة حرارة (من 2الي 8 درجة مئوية)<br />لا تستخدم إمتس بعد تاريخ انتهاء الصلاحية المذكورة على القارورة وعلى الصندوق بعد ((EXP<br />يشير تاريخ انتهاء الصلاحية الي اخر يوم في ذلك الشهر&nbsp;<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما يحتويه إمتس&nbsp;<br />الماًدة الفعالة هي إرينوتيكان هيدروكلوريد&nbsp;<br />المكونات الأخرى هي سوربيتول، حمض اللاكتيك، هيدروكسيد الصوديوم، حمض الهيدروكلوريك، والماًء للحقن.<br />ما هو شكل إمتس وماهي محتويات العبوة الخاصة به<br />إمتس هو سائل في قارورة مع سدادة مطاطية كل قارورة 2 مل تحتوي على 43 مجم من إجينتيكن أو قارورة 5 مل تحتوي على 133 مجم من إجينتيكن<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>--------</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل الترخيص التسويق&nbsp;<br />شركة إميكور للأدوية شركة محدودة<br />PLOT NO.P-2, L.T.B.T Park,Phase ll, MlDC, Hinjwadi<br />Pune 411057, Maharashtra, India<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            وقد تم اعتماد هذه النشرة بتاريخ 12/2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                IMTUS
Irinotecan hydrochloride Injection 40mg/2ml, 100mg/5ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml. contains:
Irinotecan hydrochloride USP (as trihydrate) 20mg
Water for Injection USP q.s. to 1ml
For excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion.
Pale yellow, clear aqueous solution, free from visible particles.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapeutic indications<br />Irinotecan 20 mg/mL concentrate for solution for infusion is indicated for the<br />treatment of patients with advanced colorectal cancer:<br />&bull; In combination with 5-fluorouracil and folinic acid in patients without prior<br />chemotherapy for advanced disease,<br />&bull; As a single agent in patients who have failed an established 5-fluorouracil<br />containing treatment regimen.<br />Irinotecan 20 mg/mL concentrate for solution for infusion in combination with<br />cetuximab is indicated for the treatment of patients with epidermal growth factor<br />receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer, who had<br />WARNING: DIARRHEA AND MYELOSUPPRESSION<br />Early and late forms of diarrhea can occur. Early diarrhea may be accompanied by<br />cholinergic symptoms which may be prevented or ameliorated by atropine. Late diarrhea<br />can be life threatening and should be treated promptly with loperamide.Monitor patients<br />with diarrhea and give fluid and electrolytes as needed. Institute antibiotic therapy if<br />patients develop ileus, fever, or severe neutropenia. Interrupt irinotecan hydrochloride<br />injection and reduce subsequent doses if severe diarrhea occurs.<br />Severe myelosuppression may occur.<br />not received prior treatment for metastatic disease or after failure of irinotecanincluding<br />cytotoxic therapy (see section 5.1).<br />Irinotecan 20 mg/mL concentrate for solution for infusion in combination with 5-<br />fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of<br />patients with metastatic carcinoma of the colon or rectum.<br />Irinotecan 20 mg/mL concentrate for solution for infusion in combination with<br />capecitabine with or without bevacizumab is indicated for first-line treatment of<br />patients with metastatic colorectal carcinoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For adults only. Irinotecan 20 mg/mL concentrate for solution for infusion should be<br />infused into a peripheral or central vein.<br />Recommended dosage:<br />In monotherapy (for previously treated patient):<br />The recommended dosage of irinotecan is 350 mg/m&sup2; administered as an intravenous<br />infusion over a 30- to 90 minute period every three weeks (see sections 4.4 and 6.6).<br />In combination therapy (for previously untreated patient):<br />Safety and efficacy of Irinotecan in combination with 5-fluorouracil (5FU) and folinic<br />acid (FA) have been assessed with the following schedule (see section 5.1):<br />&bull; Irinotecan plus 5FU/FA in every 2 weeks schedule.<br />The recommended dose of irinotecan is 180 mg/m&sup2; administered once every 2 weeks<br />as an intravenous infusion over a 30- to 90-minute period, followed by infusion with<br />folinic acid and 5-fluorouracil.<br />For the posology and method of administration of concomitant cetuximab, refer to the<br />product information for this medicinal product.<br />Normally, the same dose of irinotecan is used as administered in the last cycles of the<br />prior irinotecan-containing regimen. Irinotecan must not be administered earlier than<br />1 hour after the end of the cetuximab infusion.<br />For the posology and method of administration of bevacizumab, refer to the<br />bevacizumab summary product of characteristics.<br />For the posology and method of administration of capecitabine combination, please<br />see section 5.1 and refer to the appropriate sections in the capecitabine summary of<br />product characteristics.<br />Dosage adjustments:<br />Irinotecan should be administered after appropriate recovery of all adverse events to<br />grade 0 or 1 NCI-CTC grading (National Cancer Institute Common Toxicity Criteria)<br />and when treatment-related diarrhoea is fully resolved.<br />At the start of a subsequent infusion of therapy, the dose of Irinotecan concentrate for<br />solution for infusion, and 5FU when applicable, should be decreased according to the<br />worst grade of adverse events observed in the prior infusion. Treatment should be<br />delayed by 1 to 2 weeks to allow recovery from treatment-related adverse events.<br />With the following adverse events a dose reduction of 15 to 20% should be applied<br />for irinotecan and/or 5FU when applicable:<br />&bull; haematological toxicity [neutropenia grade 4, febrile neutropenia (neutropenia grade<br />3-4 and fever grade 2-4), thrombocytopenia and leukopenia (grade 4)],<br />&bull; non haematological toxicity (grade 3-4).<br />Recommendations for dose modifications of cetuximab when administered in<br />combination with irinotecan must be followed according to the product information<br />for this medicinal product.<br />In combination with capecitabine for patients 65 years of age or more, a reduction of<br />the starting dose of capecitabine to 800 mg/m2 twice daily is recommended according<br />to the summary of product characteristics for capecitabine. Refer also to the<br />recommendations for dose modifications in combination regimen given in the<br />summary of product characteristics for capecitabine.<br />Treatment Duration:<br />Treatment with irinotecan should be continued until there is an objective progression<br />of the disease or an unacceptable toxicity.<br />Special populations:<br />Patients with Impaired Hepatic Function<br />In monotherapy: Blood bilirubin levels [up to 3 times the upper limit of the normal<br />range (UNL)] in patients with performance status &le; 2, should determine the starting<br />dose of Irinotecan concentrate for solution for infusion. In these patients with<br />hyperbilirubinemia and prothrombin time greater than 50%, the clearance of<br />irinotecan is decreased (see section 5.2) and therefore the risk of hematotoxicity is<br />increased. Thus, weekly monitoring of complete blood counts should be conducted in<br />this patient population.<br />&bull; In patients with bilirubin up to 1.5 times the upper limit of the normal range (ULN),<br />the recommended dosage of irinotecan is 350 mg/m&sup2;,<br />&bull; In patients with bilirubin ranging from 1.5 to 3 times the ULN, the recommended<br />dosage of irinotecan is 200 mg/m&sup2;,<br />&bull; Patients with bilirubin beyond to 3 times the ULN should not be treated with<br />irinotecan (see sections 4.3 and 4.4).<br />No data are available in patients with hepatic impairment treated by irinotecan in<br />combination.<br />Patients with Impaired Renal Function<br />Irinotecan is not recommended for use in patients with impaired renal function, as<br />studies in this population have not been conducted. (See sections 4.4 and 5.2)<br />Elderly<br />No specific pharmacokinetic studies have been performed in elderly. However, the<br />dose should be chosen carefully in this population due to their greater frequency of<br />decreased biological functions. This population should require more intense<br />surveillance (see section 4.4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Chronic inflammatory bowel disease and/or bowel obstruction (see section 4.4)
• History of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate or
to one of the excipients.
• Lactation (see sections 4.4 and 4.6).
• Bilirubin > 3 times the upper limit of the normal range (see section 4.4).
• Severe bone marrow failure.
• WHO performance status > 2.
• Concomitant use with St John's Wort (see section 4.5).
For additional contraindications of cetuximab or bevacizumab or capecitabine, refer
to the product information for these medicinal products.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of irinotecan should be confined to units specialised in the administration of<br />cytotoxic chemotherapy and it should only be administered under the supervision of a<br />physician qualified in the use of anticancer chemotherapy.<br />Given the nature and incidence of adverse events, irinotecan will only be prescribed in<br />the following cases after the expected benefits have been weighted against the<br />possible therapeutic risks:<br />&bull; in patients presenting a risk factor, particularly those with a WHO performance<br />status = 2.<br />&bull; in the few rare instances where patients are deemed unlikely to observe<br />recommendations regarding management of adverse events (need for immediate and<br />prolonged antidiarrhoeal treatment combined with high fluid intake at onset of<br />delayed diarrhoea). Strict hospital supervision is recommended for such patients.<br />When irinotecan is used in monotherapy, it is usually prescribed with the every-3-<br />week-dosage schedule. However, the weekly-dosage schedule (see section 5) may be<br />considered in patients who may need a closer follow-up or who are at particular risk<br />of severe neutropenia.<br />Delayed diarrhoea<br />Patients should be made aware of the risk of delayed diarrhoea occurring more than<br />24 hours after the administration of irinotecan and at any time before the next cycle.<br />In monotherapy, the median time of onset of the first liquid stool was on day 5 after<br />the infusion of irinotecan. Patients should quickly inform their physician of its<br />occurrence and start appropriate therapy immediately.<br />Patients with an increased risk of diarrhoea are those who had a previous<br />abdominal/pelvic radiotherapy, those with baseline hyperleucocytosis, those with<br />performance status &ge; 2 and women. If not properly treated, diarrhoea can be lifethreatening,<br />especially if the patient is concomitantly neutropenic.<br />As soon as the first liquid stool occurs, the patient should start drinking large volumes<br />of beverages containing electrolytes and an appropriate antidiarrhoeal therapy must be<br />initiated immediately. This antidiarrhoeal treatment will be prescribed by the<br />department where irinotecan has been administered. After discharge from the hospital,<br />the patients should obtain the prescribed drugs so that they can treat the diarrhoea as<br />soon as it occurs. In addition, they must inform their physician or the department<br />administering irinotecan when/if diarrhoea is occurring.<br />The currently recommended antidiarrhoeal treatment consists of high doses of<br />loperamide (4 mg for the first intake and then 2 mg every 2 hours). This therapy<br />should continue for 12 hours after the last liquid stool and should not be modified. In<br />no instance should loperamide be administered for more than 48 consecutive hours at<br />these doses, because of the risk of paralytic ileus, nor for less than 12 hours.<br />In addition to the anti-diarrhoeal treatment, a prophylactic broad spectrum antibiotic<br />should be given, when diarrhoea is associated with severe neutropenia (neutrophil<br />count &lt; 500 cells/mm&sup3;).<br />In addition to the antibiotic treatment, hospitalisation is recommended for<br />management of the diarrhoea, in the following cases:<br />&minus; Diarrhoea associated with fever,<br />&minus; Severe diarrhoea (requiring intravenous hydration),<br />&minus; Diarrhoea persisting beyond 48 hours following the initiation of high-dose<br />loperamide therapy.<br />Loperamide should not be given prophylactically, even in patients who experienced<br />delayed diarrhoea at previous cycles.<br />In patients who experienced severe diarrhoea, a reduction in dose is recommended for<br />subsequent cycles (see section 4.2).<br />Haematology<br />Weekly monitoring of complete blood cell counts is recommended during irinotecan<br />treatment. Patients should be aware of the risk of neutropenia and the significance of<br />fever. Febrile neutropenia (temperature &gt; 38&deg;C and neutrophil count &le; 1,000<br />cells/mm&sup3;) should be urgently treated in the hospital with broad-spectrum intravenous<br />antibiotics.<br />In patients who experienced severe haematological events, a dose reduction is<br />recommended for subsequent administration (see section 4.2).<br />There is an increased risk of infections and haematological toxicity in patients with<br />severe diarrhoea. In patients with severe diarrhoea, complete blood cell counts should<br />be performed.<br />Liver impairment<br />Liver function tests should be performed at baseline and before each cycle.<br />Weekly monitoring of complete blood counts should be conducted in patients with<br />bilirubin ranging from 1.5 to 3 times ULN, due to decrease of the clearance of<br />irinotecan (see section 5.2) and thus increasing the risk of hematotoxicity in this<br />population. For patients with a bilirubin &gt; 3 times ULN (see section 4.3).<br />Nausea and vomiting<br />A prophylactic treatment with antiemetics is recommended before each treatment with<br />irinotecan. Nausea and vomiting have been frequently reported. Patients with<br />vomiting associated with delayed diarrhoea should be hospitalised as soon as possible<br />for treatment.<br />Acute cholinergic syndrome<br />If acute cholinergic syndrome appears (defined as early diarrhoea and various other<br />signs and symptoms such as sweating abdominal cramping, myosis and salivation),<br />atropine sulphate (0.25 mg subcutaneously) should be administered unless clinically<br />contraindicated (see section 4.8).<br />Caution should be exercised in patients with asthma. In patients who experienced an<br />acute and severe cholinergic syndrome, the use of prophylactic atropine sulphate is<br />recommended with subsequent doses of irinotecan.<br />Respiratory disorders<br />Interstitial pulmonary disease presenting as pulmonary infiltrates is uncommon during<br />irinotecan therapy. Interstitial pulmonary disease can be fatal. Risk factors possibly<br />associated with the development of interstitial pulmonary disease include the use of<br />pneumotoxic drugs, radiation therapy and colony stimulating factors. Patients with<br />risk factors should be closely monitored for respiratory symptoms before and during<br />irinotecan therapy.<br />Extravasation<br />While irinotecan is not a known vesicant, care should be taken to avoid extravasation<br />and the infusion site should be monitored for signs of inflammation. Should<br />extravasation occur, flushing the site and application of ice is recommended.<br />Elderly<br />Due to the greater frequency of decreased biological functions, in particular hepatic<br />function, in elderly patients, dose selection with Irinotecan concentrate for solution<br />for infusion should be cautious in this population (see section 4.2).<br />Chronic inflammatory bowel disease and/or bowel obstruction<br />Patients must not be treated with irinotecan until resolution of the bowel obstruction<br />(see section 4.3).<br />Patients with Impaired Renal Function<br />Studies in this population have not been conducted (see sections 4.2 and 5.2).<br />Cardiac Disorders<br />Myocardial ischaemic events have been observed following irinotecan therapy<br />predominately in patients with underlying cardiac disease, other known risk factors<br />for cardiac disease, or previous cytotoxic chemotherapy (see section 4.8).<br />Consequently, patients with known risk factors should be closely monitored, and<br />action should be taken to try to minimize all modifiable risk factors (e.g. smoking,<br />hypertension, and hyperlipidaemia)<br />Immunosuppressant Effects/Increased Susceptibility to Infections<br />Administration of live or live-attenuated vaccines in patients immunocompromised by<br />chemotherapeutic agents including irinotecan, may result in serious or fatal infections.<br />Vaccination with a live vaccine should be avoided in patients receiving irinotecan.<br />Killed or inactivated vaccines may be administered; however, the response to such<br />vaccines may be diminished.<br />Others<br />Since this medicinal contains sorbitol, it is unsuitable in hereditary fructose<br />intolerance. Infrequent cases of renal insufficiency, hypotension or circulatory failure<br />have been observed in patients who experienced episodes of dehydration associated<br />with diarrhoea and/or vomiting, or sepsis. Contraceptive measures must be taken<br />during and for at least three months after cessation of therapy.<br />Concomitant administration of irinotecan with a strong inhibitor (e.g. ketoconazole)<br />or inducer (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, St John&#39;s Wort)<br />of CYP3A4 may alter the metabolism of irinotecan and should be avoided (see<br />section 4.5).<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction between irinotecan and neuromuscular blocking agents cannot be ruled<br />out. Since irinotecan has anticholinesterase activity, drugs with anticholinesterase<br />activity may prolong the neuromuscular blocking effects of suxamethonium and the<br />neuromuscular blockade of non-depolarising drugs may be antagonised.<br />Several studies have shown that concomitant administration of CYP3A-inducing<br />anticonvulsant drugs (e.g., carbamazepine, phenobarbital or phenytoin) leads to<br />reduced exposure to irinotecan, SN-38 and SN-38 glucuronide and reduced<br />pharmacodynamic effects. The effects of such anticonvulsant drugs was reflected by a<br />decrease in AUC of SN-38 and SN-38G by 50% or more. In addition to induction of<br />cytochrome P450 3A enzymes, enhanced glucuronidation and enhanced biliary<br />excretion may play a role in reducing exposure to irinotecan and its metabolites.<br />A study has shown that the co-administration of ketoconazole resulted in a decrease in<br />the AUC of APC of 87% and in an increase in the AUC of SN-38 of 109% in<br />comparison to irinotecan given alone.<br />Caution should be exercised in patients concurrently taking drugs known to inhibit<br />(e.g., ketoconazole) or induce (e.g., rifampicin, carbamazepine, phenobarbital or<br />phenytoin) drug metabolism by cytochrome P450 3A4. Concurrent administration of<br />irinotecan with an inhibitor/inducer of this metabolic pathway may alter the<br />metabolism of irinotecan and should be avoided (see section 4.4).<br />In a small pharmacokinetic study (n=5), in which irinotecan 350 mg/m2 was co<br />administered with St. John&#39;s Wort (Hypericum perforatum) 900 mg, a 42% decrease<br />in the active metabolite of irinotecan, SN-38, plasma concentrations was observed.<br />St. John&#39;s Wort decreases SN-38 plasma levels. As a result, St. John&#39;s Wort should not<br />be administered with irinotecan (see section 4.3).<br />Co-administration of 5-fluorouracil/folinic acid in the combination regimen does not<br />change the pharmacokinetics of irinotecan.<br />Atazanavir sulphate. Coadministration of atazanavir sulfate, a CYP3A4 and UGT1A1<br />inhibitor, has the potential to increase systemic exposure to SN-38, the active<br />metabolite of irinotecan. Physicians should take this into consideration when coadministering<br />these drugs.<br />Interactions common to all cytotoxics:<br />The use of anticoagulants is common due to increased risk of thrombotic events in<br />tumoral diseases. If vitamin K antagonist anticoagulants are indicated, an increased<br />frequency in the monitoring of INR (International Normalised Ratio) is required due<br />to their narrow therapeutic index, the high intra-individual variability of blood<br />thrombogenicity and the possibility of interaction between oral anticoagulants and<br />anticancer chemotherapy.<br />Concomitant use contraindicated<br />- Yellow fever vaccine: risk of fatal generalised reaction to vaccines<br />Concomitant use not recommended<br />- Live attenuated vaccines (except yellow fever): risk of systemic, possible fatal<br />disease (eg-infections). This risk is increased in subjects who are already<br />immunosuppressed by their underlying disease.<br />Use an inactivated vaccine where this exists (poliomyelitis)<br />- Phenytoin: Risk of exacerbation of convulsions resulting from the decrease of<br />phenytoin digestive absorption by cytotoxic drug or risk of toxicity enhancement due<br />to increased hepatic metabolism by phenytoin.<br />Concomitant use to take into consideration<br />- Ciclosporine, Tacrolimus: Excessive immunosuppression with risk of<br />lymphoproliferation.<br />There is no evidence that the safety profile of irinotecan is influenced by cetuximab or<br />vice versa.<br />Results from a dedicated drug-drug interaction trial demonstrated no significant effect<br />of bevacizumab on the pharmacokinetics of irinotecan and its active metabolite SN-<br />38. However, this does not preclude any increase of toxicities due to their<br />pharmacological properties.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Category D<br />There is no data from the use of irinotecan in pregnant women. Irinotecan has been<br />shown to be embryotoxic and teratogenic in animals. Therefore, based on results from<br />animal studies and the mechanism of action of irinotecan, Irinotecan concentrate for<br />solution for infusion should not be used during pregnancy unless clearly necessary.<br />Women of child-bearing potential<br />Women of childbearing potential and men have to use effective contraception during<br />and up to 1 month and 3 months after treatment respectively.<br />Lactation<br />In lactating rats, 14C-irinotecan was detected in milk. It is not known whether<br />irinotecan is excreted in human milk. Consequently, because of the potential for<br />adverse reactions in nursing infants, breast-feeding must be discontinued for the<br />duration of irinotecan therapy (see section 4.3)<br />Fertility<br />There are no human data on the effect of irinotecan on fertility. In animals adverse<br />effects of irinotecan on the fertility of offspring has been documented (see section<br />5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be warned about the potential for dizziness or visual disturbances<br />which may occur within 24 hours following the administration of irinotecan, and<br />advised not to drive or operate machinery if these symptoms occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects detailed in this section refer to irinotecan. There is no evidence<br />that the safety profile of irinotecan is influenced by cetuximab or vice versa. In<br />combination with cetuximab, additional reported undesirable effects were those<br />expected with cetuximab (such as acneform rash 88%). For information on adverse<br />reactions on irinotecan in combination with cetuximab, also refer to their respective<br />summaries of product characteristics.<br />For information on adverse reactions in combination with bevacizumab, refer to the<br />bevacizumab summary of product characteristics.<br />Adverse drug reactions reported in patients treated with capecitabine in combination<br />with irinotecan in addition to those seen with capecitabine monotherapy or seen at a<br />higher frequency grouping compared to capecitabine monotherapy include: Very<br />common, all grade adverse drug reactions: thrombosis/embolism; Common, all grade<br />adverse drug reactions: hypersensitivity reaction, cardiac ischemia/infarction;<br />Common, grade 3 and grade 4 adverse drug reactions: febrile neutropenia. For<br />complete information on adverse reactions of capecitabine, refer to the capecitabine<br />summary product of characteristics.<br />Grade 3 and Grade 4 adverse drug reactions reported in patients treated with<br />capecitabine in combination with irinotecan and bevacizumab in addition to those<br />seen with capecitabine monotherapy or seen at a higher frequency grouping compared<br />to capecitabine monotherapy include: Common, grade 3 and grade 4 adverse drug<br />reactions: neutropenia, thrombosis/embolism, hypertension, and cardiac<br />ischemia/infarction. For complete information on adverse reactions of capecitabine<br />and bevacizumab, refer to the respective capecitabine and bevacizumab summary of<br />product characteristics.<br />The following adverse reactions considered to be possibly or probably related to the<br />administration of irinotecan have been reported from 765 patients at the<br />recommended dose of 350 mg/m&sup2; in monotherapy, and from 145 patients treated by<br />irinotecan in combination therapy with 5FU/FA in every 2 weeks schedule at the<br />recommended dose of 180 mg/m&sup2;.<br />Gastrointestinal Disorders<br />Delayed diarrhoea<br />Diarrhoea (occurring more than 24 hours after administration) is a dose-limiting<br />toxicity of Irinotecan concentrate for solution for infusion.<br />In monotherapy:<br />Severe diarrhoea was observed in 20% of patients who follow recommendations for<br />the management of diarrhoea. Of the evaluable cycles, 14% have a severe diarrhoea.<br />The median time of onset of the first liquid stool was on day 5 after the infusion of<br />irinotecan.<br />In combination therapy:<br />Severe diarrhoea was observed in 13.1% of patients who follow recommendations for<br />the management of diarrhoea. Of the evaluable cycles, 3.9% have a severe diarrhoea.<br />Uncommon cases of pseudo-membranous colitis have been reported, one of which<br />has been documented bacteriologically (Clostridium difficile).<br />Nausea and vomiting<br />In monotherapy:<br />Nausea and vomiting were severe in approximately 10% of patients treated with<br />antiemetics.<br />In combination therapy:<br />A lower incidence of severe nausea and vomiting was observed (2.1% and 2.8% of<br />patients respectively).<br />Dehydration<br />Episodes of dehydration commonly associated with diarrhoea and/or vomiting have<br />been reported.<br />Infrequent cases of renal insufficiency, hypotension or cardio-circulatory failure have<br />been observed in patients who experienced episodes of dehydration associated with<br />diarrhoea and/or vomiting.<br />Other gastrointestinal disorders<br />Constipation relative to irinotecan and/or loperamide has been observed, shared<br />between:<br />&bull; in monotherapy : in less than 10% of patients<br />&bull; in combination therapy : 3.4% of patients.<br />Infrequent cases of intestinal obstruction, ileus, or gastrointestinal haemorrhage and<br />rare cases of colitis, including typhlitis, ischemic and ulcerative colitis, were reported.<br />Rare cases of intestinal perforation were reported. Other mild effects include<br />anorexia, abdominal pain and mucositis.<br />Rare cases of symptomatic or asymptomatic pancreatitis have been associated with<br />irinotecan therapy.<br />Blood Disorders<br />Neutropenia is a dose-limiting toxic effect. Neutropenia was reversible and not<br />cumulative; the median day to nadir was 8 days whatever the use in monotherapy or<br />in combination therapy.<br />In monotherapy:<br />Neutropenia was observed in 78.7% of patients and was severe (neutrophil count &lt;<br />500 cells/mm3) in 22.6% of patients. Of the evaluable cycles, 18% had a neutrophil<br />count below 1,000 cells/mm&sup3; including 7.6% with a neutrophil count &lt; 500 cells/mm&sup3;.<br />Total recovery was usually reached by day 22.<br />Fever with severe neutropenia was reported in 6.2% of patients and in 1.7% of cycles.<br />Infectious episodes occurred in about 10.3% of patients (2.5% of cycles) and were<br />associated with severe neutropenia in about 5.3% of patients (1.1% of cycles), and<br />resulted in death in 2 cases.<br />Anaemia was reported in about 58.7% of patients (8% with haemoglobin &lt; 8 g/dl and<br />0.9% with haemoglobin &lt; 6.5 g/dl).<br />Thrombocytopenia (&lt; 100,000 cells/mm&sup3;) was observed in 7.4% of patients and 1.8%<br />of cycles with 0.9% with platelets count &le; 50,000 cells/mm3 and 0.2% of cycles.<br />Nearly all the patients showed a recovery by day 22.<br />In combination therapy:<br />Neutropenia was observed in 82.5% of patients and was severe (neutrophil count &lt;<br />500 cells/mm3) in 9.8% of patients.<br />Of the evaluable cycles, 67.3% had a neutrophil count below 1,000 cells/mm&sup3;<br />including 2.7% with a neutrophil count &lt; 500 cells/mm&sup3;.<br />Total recovery was usually reached within 7-8 days.<br />Fever with severe neutropenia was reported in 3.4% of patients and in 0.9% of cycles.<br />Infectious episodes occurred in about 2% of patients (0.5% of cycles) and were<br />associated with severe neutropenia in about 2.1% of patients (0.5% of cycles), and<br />resulted in death in 1 case.<br />Anaemia was reported in 97.2% of patients (2.1% with haemoglobin &lt; 8 g/dl).<br />Thrombocytopenia (&lt; 100,000 cells/mm&sup3;) was observed in 32.6% of patients and<br />21.8% of cycles. No severe thrombocytopenia (&lt; 50,000 cells/mm&sup3;) has been<br />observed.<br />One case of peripheral thrombocytopenia with antiplatelet antibodies has been<br />reported in the post-marketing experience.<br />Infection and Infestation<br />Infrequent cases of renal insufficiency, hypotension or cardio-circulatory failure have<br />been observed in patients who experienced sepsis.<br />General Disorders and Infusion Site Reactions<br />Acute cholinergic syndrome<br />Severe transient acute cholinergic syndrome was observed in 9% of patients treated in<br />monotherapy and in 1.4% of patients treated in combination therapy. The main<br />symptoms were defined as early diarrhoea and various other symptoms such as<br />abdominal pain, conjunctivitis, rhinitis, hypotension, vasodilatation, sweating, chills,<br />malaise, dizziness, visual disturbances, myosis, lachrimation and increased salivation<br />occurring during or within the first 24 hours after the infusion of irinotecan. These<br />symptoms disappear after atropine administration (see section 4.4).<br />Asthenia was severe in less than 10% of patients treated in monotherapy and in 6.2%<br />of patients treated in combination therapy. The causal relationship to irinotecan has<br />not been clearly established. Fever in the absence of infection and without<br />concomitant severe neutropenia, occurred in 12% of patients treated in monotherapy<br />and in 6.2% of patients treated in combination therapy.<br />Mild infusion site reactions have been reported although uncommonly.<br />Cardiac Disorder<br />Rare cases of hypertension during or following the infusion have been reported.<br />Respiratory Disorders<br />Interstitial pulmonary disease presenting as pulmonary infiltrates is uncommon during<br />irinotecan therapy. Early effects such as dyspnoea have been reported (see section<br />4.4).<br />Skin and Subcutaneous Tissue Disorders<br />Alopecia was very common and reversible. Mild cutaneous reactions have been<br />reported although uncommonly.<br />Immune System Disorders<br />Uncommon mild allergy reactions and rare cases of anaphylactic/anaphylactoid<br />reactions have been reported.<br />Musculoskeletal Disorders<br />Early effects such as muscular contraction or cramps and paresthesia have been<br />reported.<br />Laboratory Tests<br />In monotherapy, transient and mild to moderate increases in serum levels of either<br />transaminases, alkaline phosphatase or bilirubin were observed in 9.2%, 8.1% and<br />1.8% of the patients, respectively, in the absence of progressive liver metastasis.<br />Transient and mild to moderate increases of serum levels of creatinine have been<br />observed in 7.3% of the patients.<br />In combination therapy transient serum levels (grades 1 and 2) of either SGPT,<br />SGOT, alkaline phosphatase or bilirubin were observed in 15%, 11%, 11% and 10%<br />of the patients, respectively, in the absence of progressive liver metastasis. Transient<br />grade 3 were observed in 0%, 0%, 0% and 1% of the patients, respectively. No grade<br />4 was observed.<br />Increases of amylase and/or lipase have been very rarely reported.<br />Rare cases of hypokalemia and hyponatremia mostly related with diarrhea and<br />vomiting have been reported.<br />Nervous System Disorders<br />There have been very rare postmarketing reports of transient speech disorders<br />associated with irinotecan infusions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been reports of overdosage at doses up to approximately twice the<br />recommended therapeutic dose, which may be fatal. The most significant adverse<br />reactions reported were severe neutropenia and severe diarrhoea. There is no known<br />antidote for irinotecan. Maximum supportive care should be instituted to prevent<br />dehydration due to diarrhoea and to treat any infectious complications.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic properties<br />Cytostatic topoisomerase I inhibitor. ATC Code: L01XX19<br />Experimental data<br />Irinotecan is a semi-synthetic derivative of camptothecin. It is an antineoplastic agent<br />which acts as a specific inhibitor of DNA topoisomerase I. It is metabolised by<br />carboxylesterase in most tissues to SN-38, which was found to be more active than<br />irinotecan in purified topoisomerase I and more cytotoxic than irinotecan against<br />several murine and human tumour cell lines. The inhibition of DNA topoisomerase I<br />by irinotecan or SN-38 induces single-strand DNA lesions which blocks the DNA<br />replication fork and are responsible for the cytotoxicity. This cytotoxic activity was<br />found time-dependent and was specific to the S phase.<br />In vitro, irinotecan and SN-38 were not found to be significantly recognised by the P -<br />glycoprotein MDR, and displays cytotoxic activities against doxorubicin and<br />vinblastine resistant cell lines.<br />Furthermore, irinotecan has a broad antitumor activity in vivo against murine tumour<br />models (P03 pancreatic ductal adenocarcinoma, MA16/C mammary adenocarcinoma,<br />C38 and C51 colon adenocarcinomas) and against human xenografts (Co-4 colon<br />adenocarcinoma, Mx-1 mammary adenocarcinoma, ST-15 and SC-16 gastric<br />adenocarcinomas). Irinotecan is also active against tumors expressing the Pglycoprotein<br />MDR (vincristine- and doxorubicin-resistant P388 leukaemia&#39;s).<br />Beside the antitumor activity of irinotecan, the most relevant pharmacological effect<br />of irinotecan is the inhibition of acetylcholinesterase.<br />Clinical data<br />In combination therapy for the first-line treatment of metastatic colorectal carcinoma<br />In combination therapy with Folinic Acid and 5-Fluorouracil:<br />A phase III study was performed in 385 previously untreated metastatic colorectal<br />cancer patients treated with either every 2 weeks schedule (see section 4.2) or weekly<br />schedule regimens. In the every 2 weeks schedule, on day 1, the administration of<br />irinotecan at 180 mg/m&sup2; once every 2 weeks is followed by infusion with folinic acid<br />(200 mg/m&sup2; over a 2-hour intravenous infusion) and 5-fluorouracil (400 mg/m&sup2; as an<br />intravenous bolus, followed by 600 mg/m&sup2; over a 22-hour intravenous infusion). On<br />day 2, folinic acid and 5-fluorouracil are administered at the same doses and<br />schedules. In the weekly schedule, the administration of irinotecan at 80 mg/m&sup2; is<br />followed by infusion with folinic acid (500 mg/m&sup2; over a 2-hour intravenous infusion)<br />and then by 5-fluorouracil (2300 mg/m&sup2; over a 24-hour intravenous infusion) over 6<br />weeks.<br />In the combination therapy trial with the 2 regimens described above, the efficacy of<br />irinotecan was evaluated in 198 treated patients:</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The intensity of the major toxicities encountered with irinotecan (e.g., leukoneutropenia and diarrhoea) is related to the exposure (AUC) to parent drug and metabolite SN-38. Significant correlations were observed between haematological toxicity (decrease in white blood cells and neutrophils at nadir) or diarrhoea intensity and both irinotecan and metabolite SN-38 AUC values in monotherapy.<br />&nbsp;<br />Patients with Reduced UGT1A1 Activity<br />Uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) is involved in the metabolic deactivation of SN-38, the active metabolite of irinotecan to inactive SN-38 glucuronide (SN-38G). The UGT1A1 gene is highly polymorphic, resulting in variable metabolic capacities among individuals. One specific variation of the UGT1A1 gene includes a polymorphism in the promoter region known as the UGT1A1*28 variant. This variant and other congenital deficiencies in UGT1A1 expression (such as Crigler-Najjar and Gilbert&#39;s syndrome) are associated with reduced activity of this enzyme. Data from a meta analysis indicate that individuals with Crigler-Najjar syndrome (types 1 and 2) or those who are homozygous for the UGT1A1*28 allele (Gilbert&#39;s syndrome) are at increased risk of haematological toxicity (grades 3 and 4) following administration of irinotecan at moderate or high doses (&gt;150 mg/m2). A relationship between UGT1A1 genotype and the occurrence of irinotecan induced diarrhoea was not established.</p><p>Patients known to be homozygous for UGT1A1*28 should be administered the normally indicated irinotecan starting dose. However, these patients should be monitored for haematologic toxicities. A reduced irinotecan starting dose should be considered for patients who have experienced prior haematologic toxicity with previous treatment. The exact reduction in starting dose in this patient population has not been established and any subsequent dose modifications should be based on a patient&#39;s tolerance of the treatment (see sections 4.2 and 4.4).</p><p>There is at present insufficient data to conclude on clinical utility of UGT1A1 genotyping.</p><p>5.2 Pharmacokinetic properties<br />In a phase I study in 60 patients with a dosage regimen of a 30-minute intravenous infusion of 100 to 750 mg/m&sup2; every three weeks, irinotecan showed a biphasic or thriphasic elimination profile. The mean plasma clearance was 15 L/h/m&sup2; and the volume of distribution at steady state (Vss): 157 L/m&sup2;. The mean plasma half-life of the first phase of the triphasic model was 12 minutes, of the second phase 2.5 hours, and the terminal phase half-life was 14.2 hours. SN-38 showed a biphasic elimination profile with a mean terminal elimination half-life of 13.8 hour s. At the end of the infusion, at the recommended dose of 350 mg/m&sup2;, the mean peak plasma concentrations of irinotecan and SN-38 were 7.7 &micro; g/ml and 56 ng/ml, respectively, and the mean area under the curve (AUC) values were 34 &micro; g.h/ml and 451 ng.h/ml, respectively. A large interindividual variability in pharmacokinetic parameters is generally observed for SN-38.</p><p>A population pharmacokinetic analysis of irinotecan has been performed in 148 patients with metastatic colorectal cancer, treated with various schedules and at different doses in phase II trials. Pharmacokinetic parameters estimated with a three<br />&nbsp;<br />compartment model were similar to those observed in phase I studies. All studies have shown that irinotecan (CPT-11) and SN-38 exposure increase proportionally with CPT-11 administered dose; their pharmacokinetics are independent of the number of previous cycles and of the administration schedule.</p><p>In vitro, plasma protein binding for irinotecan and SN-38 was approximately 65% and 95% respectively.</p><p>Mass balance and metabolism studies with 14 C-labelled drug have shown that more than 50% of an intravenously administered dose of irinotecan is excreted as unchanged drug, with 33% in the faeces mainly via the bile and 22% in urine.</p><p>Two metabolic pathways account each for at least 12% of the dose:</p><p>&bull; Hydrolysis by carboxylesterase into active metabolite SN-38,SN-38 is mainly eliminated by glucuronidation, and further by biliary and renal excretion (less than 0.5% of the irinotecan dose) The SN-38 glucuronite is subsequently probably hydrolysed in the intestine.</p><p>&bull; Cytochrome P450 3A enzymes-dependent oxidations resulting in opening of the outer piperidine ring with formation of APC (aminopentanoic acid derivate) and NPC (primary amine derivate) (see section 4.5).</p><p>Unchanged irinotecan is the major entity in plasma, followed by APC, SN-38 glucuronide and SN-38. Only SN-38 has significant cytotoxic activity.</p><p>Irinotecan clearance is decreased by about 40% in patients with bilirubinemia between 1.5 a nd 3 t imes the upper normal limit. In these patients a 200 m g/m&sup2; irinotecan dose leads to plasma drug exposure comparable to that observed at 350 mg/m&sup2; in cancer patients with normal liver parameters<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.3 Preclinical safety data<br />Irinotecan and SN-38 have been shown to be mutagenic in vitro in the chromosomal aberration test on CHO-cells as well as in the in vivo micronucleus test in mice.</p><p>However, they have been shown to be devoid of any mutagenic potential in the Ames test.</p><p>In rats treated once a week during 13 w eeks at the maximum dose of 150 m g/m&sup2; (which is less than half the human recommended dose), no treatment related tumours were reported 91 weeks after the end of treatment.</p><p>Single- and repeated-dose toxicity studies with irinotecan have been carried out in mice, rats and dogs. The main toxic effects were seen in the haematopoietic and<br />&nbsp;<br />lymphatic systems. In dogs, delayed diarrhoea associated with atrophy and focal necrosis of the intestinal mucosa was reported. Alopecia was also observed in the dog.</p><p>The severity of these effects was dose-related and reversible.<br />Reproduction<br />Irinotecan was teratogenic in rats and rabbits at doses below the human therapeutic dose. In rats, pups born to treated animals with external abnormalities showed a decrease in fertility. This was not seen in morphologically normal pups. In pregnant rats there was a decrease in placental weight and in the offspring a decrease in fetal viability and increase in behavioural abnormalities.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1 List of excipients<br />Sorbitol (E420) Lactic acid Sodium hydroxide Hydrochloric acid Water for injection<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p><p>Do not admix with other medications.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The shelf-life of unopened vials is 24 months.

Irinotecan 20 mg/ml concentrate solution for infusion Injection 20 mg/mL is intended for single use only and any unused portion should be discarded.
Irinotecan 20 m g/ml concentrate solution for infusion must be diluted prior to infusion. Irinotecan 20 mg/ml concentrate solution for infusion should be diluted in 5% Dextrose Injection, USP, (preferred) or 0.9% Sodium Chloride Injection, USP, to a final concentration range of 0.12 mg/mL to 2.8 mg/mL. Other drugs should not be added to the infusion solution.
The solution is physically and chemically stable for up t o 24 hou rs at room temperature and in ambient fluorescent lighting. Solutions diluted in 5% Dextrose Injection, USP, and stored at refrigerated temperatures (approximately 2° to 8°C, 36° to 46°F), and protected from light are physically and chemically stable for 48 hours. Refrigeration of admixtures using 0.9% Sodium Chloride Injection, USP, is not recommended due to a low and sporadic incidence of visible particulates. Freezing Irinotecan 20 mg/ml concentrate solution for infusion   and admixtures of Irinotecan 20 mg/ml concentrate solution for infusion may result in precipitation of the drug and should be avoided.
The Irinotecan 20 mg/ml concentrate solution for infusion Injection solution should be used immediately after reconstitution as it c ontains no antibacterial preservative. Because of possible microbial contamination during dilution, it is advisable to use the admixture prepared with 5% Dextrose Injection, USP, within 24 hours if refrigerated
 
(2° to 8°C, 36° t o 46°F). In the case of admixtures prepared with 5% Dextrose Injection, USP, or Sodium Chloride Injection, USP, the solutions should be used within 4 hour s if kept at room temperature. If reconstitution and dilution are performed under strict aseptic conditions (e.g., on Laminar Air Flow bench), Irinotecan 20 mg/ml concentrate solution for infusion Injection solution should be used (infusion completed) within 12 hour s at room temperature or 24 hours if refrigerated (2° to 8°C, 36° to 46°F).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />Protect from light, store in carton. Protect from freezing.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amber glass vial (type I) with rubber stopper and aluminium flip off seal. Pack sizes: 5 ml vial. Available as single pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other antineoplastic agents, irinotecan must be prepared and handled with caution. The use of glasses, mask and gloves is required.</p><p>If Irinotecan concentrate for solution for infusion should come into contact with the skin, wash immediately and thoroughly with soap and water. If irinotecan solution or infusion solution should come into contact with the mucous membranes, wash immediately with water.<br />Preparation for the intravenous infusion administration:<br />As with any other injectable drugs, THE IRINOTECAN CONCENTRATE FOR SOLUTION FOR INFUSION MUST BE PREPARED ASEPTICALLY (see section 6.3).<br />If any precipitate is observed in the vials or after dilution, the product should be discarded according to standard procedures for cytotoxic agents.</p><p>Aseptically withdraw the required amount of irinotecan solution from the vial with a calibrated syringe and inject into a 250 ml infusion bag or bottle containing either 0.9<br />% sodium chloride solution or 5% glucose solution. The infusion should then be thoroughly mixed by manual rotation.</p><p>Disposal:<br />All materials used for dilution and administration should be disposed of according to hospital standard procedures applicable to cytotoxic agents<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emcure Pharmaceuticals LTD. Hinjwadi, Pune 411057, India.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December-2013.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>